• Consensus Rating: Sell
  • Consensus Price Target: $3.00
  • Forecasted Upside: -10.71 %
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.36
▲ +0.01 (0.30%)

This chart shows the closing price for IVVD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Invivyd Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVVD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVVD

Analyst Price Target is $3.00
▼ -10.71% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Invivyd in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a -10.71% upside from the last price of $3.36.

This chart shows the closing price for IVVD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Invivyd.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2022Morgan StanleyInitiated CoverageUnderweight$3.00Low
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Invivyd

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $3.36
Low: $3.17
High: $3.37

50 Day Range

MA: N/A

52 Week Range

Now: $3.36
Low: $2.41
High: $78.82

Volume

5,613 shs

Average Volume

473,386 shs

Market Capitalization

$369.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Invivyd?

The following Wall Street sell-side analysts have issued stock ratings on Invivyd in the last year: Morgan Stanley.
View the latest analyst ratings for IVVD.

What is the current price target for Invivyd?

1 Wall Street analysts have set twelve-month price targets for Invivyd in the last year. Their average twelve-month price target is $3.00, suggesting a possible downside of 10.7%. Morgan Stanley has the highest price target set, predicting IVVD will reach $3.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Invivyd in the next year.
View the latest price targets for IVVD.

What is the current consensus analyst rating for Invivyd?

Invivyd currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe IVVD will underperform the market and that investors should sell shares of Invivyd.
View the latest ratings for IVVD.

What other companies compete with Invivyd?

How do I contact Invivyd's investor relations team?

Invivyd's physical mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The company's listed phone number is 781 819 0080 and its investor relations email address is [email protected] The official website for Invivyd is adagiotx.com. Learn More about contacing Invivyd investor relations.